These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 32039412

  • 1. NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors.
    Del Valle AC, Su CK, Sun YC, Huang YF.
    Biomater Sci; 2020 Mar 31; 8(7):1934-1950. PubMed ID: 32039412
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy and cardioprotection of nucleolin-targeted doxorubicin-loaded ultrasound nanobubbles in treating triple-negative breast cancer.
    Fang K, Wang L, Huang H, Dong S, Guo Y.
    Nanotechnology; 2021 Mar 25; 32(24):. PubMed ID: 33690196
    [Abstract] [Full Text] [Related]

  • 3. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
    Liang X, Wang Y, Shi H, Dong M, Han H, Li Q.
    Int J Nanomedicine; 2021 Mar 25; 16():2569-2584. PubMed ID: 33833512
    [Abstract] [Full Text] [Related]

  • 4. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance.
    Liao ZX, Chuang EY, Lin CC, Ho YC, Lin KJ, Cheng PY, Chen KJ, Wei HJ, Sung HW.
    J Control Release; 2015 Jun 28; 208():42-51. PubMed ID: 25637705
    [Abstract] [Full Text] [Related]

  • 5. A novel theranostic system of AS1411 aptamer-functionalized albumin nanoparticles loaded on iron oxide and gold nanoparticles for doxorubicin delivery.
    Baneshi M, Dadfarnia S, Shabani AMH, Sabbagh SK, Haghgoo S, Bardania H.
    Int J Pharm; 2019 Jun 10; 564():145-152. PubMed ID: 30978484
    [Abstract] [Full Text] [Related]

  • 6. Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types.
    Dam DH, Culver KS, Odom TW.
    Mol Pharm; 2014 Feb 03; 11(2):580-7. PubMed ID: 24422969
    [Abstract] [Full Text] [Related]

  • 7. Facile Construction of i-Motif DNA-Conjugated Gold Nanostars as Near-Infrared and pH Dual-Responsive Targeted Drug Delivery Systems for Combined Cancer Therapy.
    Miao D, Yu Y, Chen Y, Liu Y, Su G.
    Mol Pharm; 2020 Apr 06; 17(4):1127-1138. PubMed ID: 32092274
    [Abstract] [Full Text] [Related]

  • 8. A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo.
    Taghdisi SM, Danesh NM, Ramezani M, Yazdian-Robati R, Abnous K.
    Mol Pharm; 2018 May 07; 15(5):1972-1978. PubMed ID: 29669200
    [Abstract] [Full Text] [Related]

  • 9. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
    Lale SV, R G A, Aravind A, Kumar DS, Koul V.
    Biomacromolecules; 2014 May 12; 15(5):1737-52. PubMed ID: 24689987
    [Abstract] [Full Text] [Related]

  • 10. A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy.
    Trinh TL, Zhu G, Xiao X, Puszyk W, Sefah K, Wu Q, Tan W, Liu C.
    PLoS One; 2015 May 12; 10(11):e0136673. PubMed ID: 26523833
    [Abstract] [Full Text] [Related]

  • 11. Aptamer-functionalized gold nanoparticles as photoresponsive nanoplatform for co-drug delivery.
    Shiao YS, Chiu HH, Wu PH, Huang YF.
    ACS Appl Mater Interfaces; 2014 Dec 24; 6(24):21832-41. PubMed ID: 24949657
    [Abstract] [Full Text] [Related]

  • 12. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells.
    Zhang W, Wang F, Wang Y, Wang J, Yu Y, Guo S, Chen R, Zhou D.
    J Control Release; 2016 Jun 28; 232():9-19. PubMed ID: 27072026
    [Abstract] [Full Text] [Related]

  • 13. NIR-II light triggered nitric oxide release nanoplatform combined chemo-photothermal therapy for overcoming multidrug resistant cancer.
    Wang J, Wu C, Qin X, Huang Y, Zhang J, Chen T, Wang Y, Ding Y, Yao Y.
    J Mater Chem B; 2021 Feb 14; 9(6):1698-1706. PubMed ID: 33495772
    [Abstract] [Full Text] [Related]

  • 14. Targeted co-delivery of FOXM1 aptamer and DOX by nucleolin aptamer-functionalized pH-responsive biocompatible nanodelivery system to enhance therapeutic efficacy against breast cancer: in vitro and in vivo.
    Masoudi M, Taghdisi SM, Hashemitabar G, Abnous K.
    Drug Deliv Transl Res; 2024 Jun 14; 14(6):1535-1550. PubMed ID: 38161196
    [Abstract] [Full Text] [Related]

  • 15. A new NIR-triggered doxorubicin and photosensitizer indocyanine green co-delivery system for enhanced multidrug resistant cancer treatment through simultaneous chemo/photothermal/photodynamic therapy.
    Yu Y, Zhang Z, Wang Y, Zhu H, Li F, Shen Y, Guo S.
    Acta Biomater; 2017 Sep 01; 59():170-180. PubMed ID: 28629893
    [Abstract] [Full Text] [Related]

  • 16. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
    Mosafer J, Mokhtarzadeh A.
    Curr Drug Deliv; 2018 Sep 01; 15(9):1323-1329. PubMed ID: 30039760
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Co-delivery of doxorubicin and aptamer against Forkhead box M1 using chitosan-gold nanoparticles coated with nucleolin aptamer for synergistic treatment of cancer cells.
    Khademi Z, Lavaee P, Ramezani M, Alibolandi M, Abnous K, Taghdisi SM.
    Carbohydr Polym; 2020 Nov 15; 248():116735. PubMed ID: 32919550
    [Abstract] [Full Text] [Related]

  • 19. Near-infrared triggered co-delivery of doxorubicin and quercetin by using gold nanocages with tetradecanol to maximize anti-tumor effects on MCF-7/ADR cells.
    Zhang Z, Xu S, Wang Y, Yu Y, Li F, Zhu H, Shen Y, Huang S, Guo S.
    J Colloid Interface Sci; 2018 Jan 01; 509():47-57. PubMed ID: 28881205
    [Abstract] [Full Text] [Related]

  • 20. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.
    Zhou W, Zhou Y, Wu J, Liu Z, Zhao H, Liu J, Ding J.
    J Drug Target; 2014 Jan 01; 22(1):57-66. PubMed ID: 24156476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.